Conclusion
In summary, NLR can be an important biomarker for assessing the prognosis of patients with advanced tumors, especially NLR<3 is an independent risk factor for survival time of patients with treated metastatic colorectal cancer who receive immune checkpoint inhibitors. Its elevated level is usually associated with poorer prognosis, which helps doctors to develop more effective treatment strategies.